A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients

V.R. Bollineni; G M Kramer; Elise P Jansma; Y Liu; Wim J. G. Oyen

doi:10.1016/j.ejca.2015.11.018

A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients

V.R. Bollineni, G M Kramer, Elise P Jansma, Y Liu, Wim J. G. Oyen

Radiology and nuclear medicine

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Imaging biomarkers have a potential to depict the hallmarks of cancers that characterise cancer cells as compared to normal cells. One pertinent example is 3'-deoxy-3'-(18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET), which allows non-invasive in vivo assessment of tumour proliferation. Most importantly, [(18)F]FLT does not seem to be accumulating in inflammatory processes, as seen in [(18)F]-fludeoxyglucose, the most commonly used PET tracer for assessment of cell metabolism. [(18)F]FLT could therefore provide additional information about the tumour biology before, during and after treatment. This systematic review focuses on the use of [(18)F]FLT-PET tumour uptake values as a measure of tumour response to therapeutic interventions. The clinical studies which evaluated the role of [(18)F]FLT-PET as a measure of tumour response to treatment are summarised and the evidence linking [(18)F]FLT-PET tumour uptake values with clinical outcome is evaluated.

Original language	English
Pages (from-to)	81-97
Number of pages	17
Journal	European Journal of Cancer
Volume	55
DOIs	https://doi.org/10.1016/j.ejca.2015.11.018
Publication status	Published - Mar 2016

Access to Document

10.1016/j.ejca.2015.11.018

Cite this

@article{ed6df6cb053c4a2c9c4770ab8c4eec9a,

title = "A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients",

abstract = "Imaging biomarkers have a potential to depict the hallmarks of cancers that characterise cancer cells as compared to normal cells. One pertinent example is 3'-deoxy-3'-(18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET), which allows non-invasive in vivo assessment of tumour proliferation. Most importantly, [(18)F]FLT does not seem to be accumulating in inflammatory processes, as seen in [(18)F]-fludeoxyglucose, the most commonly used PET tracer for assessment of cell metabolism. [(18)F]FLT could therefore provide additional information about the tumour biology before, during and after treatment. This systematic review focuses on the use of [(18)F]FLT-PET tumour uptake values as a measure of tumour response to therapeutic interventions. The clinical studies which evaluated the role of [(18)F]FLT-PET as a measure of tumour response to treatment are summarised and the evidence linking [(18)F]FLT-PET tumour uptake values with clinical outcome is evaluated.",

keywords = "Cell Proliferation, Dideoxynucleosides, Disease-Free Survival, Humans, Neoplasms, Positron-Emission Tomography, Predictive Value of Tests, Radiopharmaceuticals, Treatment Outcome, Journal Article, Research Support, Non-U.S. Gov't, Review",

author = "V.R. Bollineni and Kramer, {G M} and Jansma, {Elise P} and Y Liu and Oyen, {Wim J. G.}",

year = "2016",

month = mar,

doi = "10.1016/j.ejca.2015.11.018",

language = "English",

volume = "55",

pages = "81--97",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Pergamon",

}

TY - JOUR

T1 - A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients

AU - Bollineni, V.R.

AU - Kramer, G M

AU - Jansma, Elise P

AU - Liu, Y

AU - Oyen, Wim J. G.

PY - 2016/3

Y1 - 2016/3

N2 - Imaging biomarkers have a potential to depict the hallmarks of cancers that characterise cancer cells as compared to normal cells. One pertinent example is 3'-deoxy-3'-(18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET), which allows non-invasive in vivo assessment of tumour proliferation. Most importantly, [(18)F]FLT does not seem to be accumulating in inflammatory processes, as seen in [(18)F]-fludeoxyglucose, the most commonly used PET tracer for assessment of cell metabolism. [(18)F]FLT could therefore provide additional information about the tumour biology before, during and after treatment. This systematic review focuses on the use of [(18)F]FLT-PET tumour uptake values as a measure of tumour response to therapeutic interventions. The clinical studies which evaluated the role of [(18)F]FLT-PET as a measure of tumour response to treatment are summarised and the evidence linking [(18)F]FLT-PET tumour uptake values with clinical outcome is evaluated.

AB - Imaging biomarkers have a potential to depict the hallmarks of cancers that characterise cancer cells as compared to normal cells. One pertinent example is 3'-deoxy-3'-(18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET), which allows non-invasive in vivo assessment of tumour proliferation. Most importantly, [(18)F]FLT does not seem to be accumulating in inflammatory processes, as seen in [(18)F]-fludeoxyglucose, the most commonly used PET tracer for assessment of cell metabolism. [(18)F]FLT could therefore provide additional information about the tumour biology before, during and after treatment. This systematic review focuses on the use of [(18)F]FLT-PET tumour uptake values as a measure of tumour response to therapeutic interventions. The clinical studies which evaluated the role of [(18)F]FLT-PET as a measure of tumour response to treatment are summarised and the evidence linking [(18)F]FLT-PET tumour uptake values with clinical outcome is evaluated.

KW - Cell Proliferation

KW - Dideoxynucleosides

KW - Disease-Free Survival

KW - Humans

KW - Neoplasms

KW - Positron-Emission Tomography

KW - Predictive Value of Tests

KW - Radiopharmaceuticals

KW - Treatment Outcome

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

KW - Review

U2 - 10.1016/j.ejca.2015.11.018

DO - 10.1016/j.ejca.2015.11.018

M3 - Article

C2 - 26820682

SN - 0959-8049

VL - 55

SP - 81

EP - 97

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -